Priorities for local immunotherapy research and drug development

<p>Local immunotherapy comprises broad classes of therapeutics that aim to trigger a robust "in situ" immune response that can ultimately generate systemic antitumor immunity. These agents are appealing as resistance to standard immune checkpoint inhibitors has been linked to a lack of baseline immune activity or immune suppressive elements in the tumor microenvironment. By administering agents directly to the tumor…